Asston Pharmaceuticals Ltd (544445)
சுருக்கம்
The board meets on 12 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 12 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- H2 FY26
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 6 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 12 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Asston Pharmaceuticals Ltd-இன் இயக்குநர் குழுக் கூட்டம் 12 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, H2 FY26, Asston Pharmaceuticals' revenue was ₹10.1 Cr (+10.8% year on year, -34.8% on the previous half-year), and net profit ₹0.5 Cr (-75.4% year on year); the operating margin was -27.9%.
| H2 FY26 (₹ கோடி) | மதிப்பு | YoY H2 FY25-உடன் | முந்தைய அரையாண்டுடன் ஒப்பீடு |
|---|---|---|---|
| வருவாய் | ₹10.1 | +10.8% | -34.8% |
| செயல்பாட்டு லாபம் | ₹-2.8 | நஷ்டமாக | நஷ்டமாக |
| நிகர லாபம் | ₹0.5 | -75.4% | — |
| EPS (₹) | 0.56 | -82.0% | — |
| செயல்பாட்டு லாப வரம்பு | -27.9% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Asston Pharmaceuticals announced that its Board of Directors approved the unaudited financial statements alongside the limited review report for the half-year ended September 30, 2026. The meeting took place on November 12, 2026, commencing at 04:00 PM and concluding at 04:20 PM. The covering disclosure does not include the detailed financial statements or figures in this excerpt. Investors will need to review the attached financial schedules to assess revenue and profitability trends against historical TTM revenue of Rs 51 Cr.
- Board meeting conducted on November 12, 2026, from 04:00 PM to 04:20 PM
- Approved Unaudited Financial Statements for the half-year ended September 30, 2026
- Limited review report for H1 ended September 30, 2026 considered and taken on record
- Detailed financial numbers were not disclosed in the cover letter text
Asston Pharmaceuticals Limited announced that its Board of Directors approved shifting the company's registered office within the local limits of Navi Mumbai. The registered office will move from CBD Belapur to Nerul, Navi Mumbai, effective October 15, 2026. This administrative change falls under the same Registrar of Companies jurisdiction. The meeting took place on October 13, 2026, lasting 20 minutes from 04:00 PM to 04:20 PM.
- Board approved shifting the registered office effective October 15, 2026
- Old office located at Office No. A-431, Balaji Bhavan, 4th Floor, Sector-11 CBD Belapur, Navi Mumbai
- New office located at Office No. 1437 and 1438, 24 High, Service Road, MIDC Industrial Area, Shiravane, Nerul, Navi Mumbai
- Board meeting commenced at 04.00 P.M. and concluded at 04.20 P.M. on October 13, 2026
Asston Pharmaceuticals has scheduled a Board of Directors meeting on October 13, 2026. The board will consider and approve the acquisition of immovable property through a bank or financial institution auction, alongside shifting the company's registered office address. Financial outlays and property details were not disclosed in the intimation. Any significant capex will be evaluated against the company's current net worth of ₹39 crore and debt of ₹5 crore.
- Board meeting scheduled for Tuesday, 13th October, 2026
- Proposal to acquire immovable property via Bank/Financial Institution Auction
- Proposal to shift the registered office address of the company
- Intimation submitted under Regulation 29(1) on 06th October, 2026
Asston Pharmaceuticals announced that shareholders at its 7th Annual General Meeting held on September 29, 2026, approved key corporate resolutions. Mr. Ashish Narayan Sakalkar was re-appointed as Managing Director under retirement by rotation provisions. Additionally, members approved the appointment of M/s Panchal S K & Associates as Statutory Auditors and cleared remuneration increases for the Managing Director, CEO, and a Non-Executive Director. The company posted FY26 revenue of Rs 25.47 crore with a net profit of Rs 3.87 crore.
- Shareholders approved resolutions at the 7th AGM held on September 29, 2026
- Re-appointment of MD Ashish Narayan Sakalkar (DIN: 06601011) retiring by rotation under section 152(6)
- Appointment of M/s Panchal S K & Associates (ICAI Reg. No. 145989W) as Statutory Auditors
- Remuneration increases approved for MD Ashish Sakalkar, CEO Saili Jayaram More, and Non-Executive Director Sachin Badakh
Asston Pharmaceuticals Limited has submitted a regulatory disclosure to the exchange under Regulation 29(1) of SEBI (SAST) Regulations, 2011. The submission follows a disclosure received by the company on August 31, 2026, from Mrs. Prakruti R Pali regarding share acquisition. The specific share volume, transaction price, and resulting ownership percentage were not detailed in the submitted cover letter.
- Disclosure under Regulation 29(1) of SEBI (SAST) Regulations submitted to BSE
- Acquisition disclosure received from Mrs. Prakruti R Pali on 31st August, 2026
- Specific acquisition size and post-transaction shareholding not disclosed in the filing extract
Asston Pharmaceuticals Ltd has scheduled a Board of Directors meeting on September 4, 2026. The agenda includes considering the appointment of M/s Panchal S K & Associates as Statutory Auditor and approving hikes in managerial remuneration for the Managing Director, CEO, and a Non-Executive Director. Additionally, the Board will approve the notice and date for the upcoming 7th Annual General Meeting.
- Board meeting scheduled for Friday, September 4, 2026
- Proposal to appoint M/s Panchal S K & Associates (FRN: 145989W) as Statutory Auditor
- To review and approve remuneration increase for MD Ashish Narayan Sakalkar and WTD & CEO Saili Jayaram More
- To approve remuneration increase for Non-Executive Director Sachin Chandrakant Badakh
- To finalize notice and schedule for convening the 7th Annual General Meeting
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
